<?xml version="1.0"?>
<rss version="2.0"><channel><title>Neue Studien: Psoriasis im JDDG</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/?d=1</link><description>Neue Studien: Psoriasis im JDDG</description><language>de</language><item><title>Evidence- and consensus-based guideline on lichen sclerosus.</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/evidence-and-consensus-based-guideline-on-lichen-sclerosus-r582/</link><description><![CDATA[The German-language, consensus- and evidence-based S3 guideline on lichen sclerosus (LS) was developed based on the European "EuroGuiDerm Guideline on lichen sclerosus" under the leadership of the German Dermatological Society (DDG) and the German Society for Gynecology and Obstetrics (DGGG). Particular emphasis was placed on adapting the recommendations to the healthcare conditions in German-speaking countries. The interdisciplinary guideline development group consisted of 24 experts from 16 medical societies and actively included patient representatives in the development process. The guideline provides comprehensive recommendations on diagnosis, patient management, follow-up care, and patient education, as well as the treatment of both genital and extragenital LS in women, men, girls, and boys. Regardless of age or sex, ultrapotent or potent topical glucocorticosteroids in combination with emollients remain the standard therapy for genital LS. In male patients with LS-associated phimosis who do not respond sufficiently to standard therapy, circumcision with complete removal of the foreskin is indicated. For extragenital LS, phototherapy with UV light is recommended as an adjunct to topical treatment. Topical calcineurin inhibitors are second-line therapy.<p><a href="http://europepmc.org/article/MED/41778748?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">582</guid><pubDate>Fri, 10 Apr 2026 10:21:31 +0000</pubDate></item><item><title>Evidenz&#x2010; und konsensbasierte (S3) Leitlinie: Lichen sclerosus</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/evidenz%E2%80%90-und-konsensbasierte-s3-leitlinie-lichen-sclerosus-r581/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/PMC/PMC13059059?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">581</guid><pubDate>Fri, 10 Apr 2026 10:21:31 +0000</pubDate></item><item><title>The role of inflammatory cell death in type 1 dominant inflammatory skin diseases.</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/the-role-of-inflammatory-cell-death-in-type-1-dominant-inflammatory-skin-diseases-r580/</link><description><![CDATA[While there has been significant progress in the development of new therapies for psoriasis and atopic dermatitis in recent years, innovation in the field of type 1 dominant skin diseases is still limited. This category comprises diseases characterized by a cytotoxic immune reaction directed against resident skin cells. The histological correlate is interface dermatitis, defined by a subepidermal inflammatory infiltrate associated with epidermal keratinocyte apoptosis. Representative conditions include lichen planus, cutaneous lupus erythematosus, erythema multiforme, alopecia areata, and vitiligo. Immunologically, there is a dominance of Th1 cells, which mediate their effects through interferon-γ and tumor necrosis factor-α. Recent findings have shown that, in addition to apoptosis, other forms of cell death are also activated by this immune response, such as necroptosis. In contrast to apoptosis, necroptosis represents a strong immunological stimulus and thus further intensifies the local inflammatory response. These findings open new therapeutic perspectives, as numerous necroptosis inhibitors are currently under investigation for various inflammatory diseases. The present review summarizes the immunopathogenesis of type 1-dominant skin diseases and highlights emerging therapeutic strategies, including the inhibition of inflammatory cell death.<p><a href="http://europepmc.org/article/MED/41937512?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">580</guid><pubDate>Fri, 10 Apr 2026 10:21:31 +0000</pubDate></item><item><title>Should TNF inhibitors be avoided in psoriasis patients with latent tuberculosis?</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/should-tnf-inhibitors-be-avoided-in-psoriasis-patients-with-latent-tuberculosis-r579/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/MED/41954303?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">579</guid><pubDate>Fri, 10 Apr 2026 10:21:31 +0000</pubDate></item><item><title>Palmoplantare Pustulose: Entstehung, Differentialdiagnose und Therapie</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/palmoplantare-pustulose-entstehung-differentialdiagnose-und-therapie-r578/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/PMC/PMC13059063?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">578</guid><pubDate>Fri, 10 Apr 2026 10:21:31 +0000</pubDate></item><item><title>Palmoplantar pustulosis: pathogenesis, differential diagnosis, and treatment.</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/palmoplantar-pustulosis-pathogenesis-differential-diagnosis-and-treatment-r577/</link><description><![CDATA[Palmoplantar pustulosis (PPP) is a chronic inflammatory and often painful disease characterized by sterile pustules on the palms and soles, significantly impairing quality of life. Women are more frequently affected than men, and smoking is a major trigger. Under biologic therapies, especially TNF antagonists, a paradoxical PPP may occur. PPP is associated with psoriasis vulgaris and may be accompanied by osteoarticular involvement. Pathogenetically, PPP likely begins around the acrosyringium, with the pustules consisting almost exclusively of infiltrating neutrophilic granulocytes attracted by chemotactic factors secreted by activated keratinocytes. Inflammation is sustained through a self-amplifying cytokine network, including interleukin (IL)-17, IL-19, and related mediators. Treatment options for PPP include topical treatments, UV-phototherapies - particularly topical PUVA (Psoralen plus UVA) therapy- and systemic therapies. Systemic agents comprise conventional treatments such as acitretin, methotrexate, fumaric acid esters, and ciclosporin, newer small molecules like apremilast and Janus kinase inhibitors, as well as biologics. Conventional systemic therapies are often not sufficiently effective in PPP and associated with side effects. Currently, among systemic therapies, only acitretin is approved for PPP. In recent years, placebo-controlled studies have demonstrated a significant effect of apremilast, brodalumab, guselkumab and risankizumab on PPP, and further studies with topical and systemic Janus kinase inhibitors as well as IL-17A/F inhibitors are underway.<p><a href="http://europepmc.org/article/MED/41948989?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">577</guid><pubDate>Fri, 10 Apr 2026 10:21:31 +0000</pubDate></item><item><title>Ixekizumab optimization in moderate-to-severe plaque psoriasis in real clinical practice: a retrospective multicenter study.</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/ixekizumab-optimization-in-moderate-to-severe-plaque-psoriasis-in-real-clinical-practice-a-retrospective-multicenter-study-r539/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/MED/41830197?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">539</guid><pubDate>Mon, 30 Mar 2026 08:02:13 +0000</pubDate></item><item><title>Psychoeducational schema therapy for psoriasis and atopic dermatitis: a randomized controlled pilot crossover trial.</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/psychoeducational-schema-therapy-for-psoriasis-and-atopic-dermatitis-a-randomized-controlled-pilot-crossover-trial-r538/</link><description><![CDATA[<h4>Background and objectives</h4>Atopic dermatitis and psoriasis are chronic inflammatory skin diseases often linked to psychological stress. Integrative care models are lacking. This randomized pilot study aimed to develop and test a psychoeducational intervention for dermatology patients.<h4>Patients and methods</h4>Patients with a PHQ-2 score ≥ 3 at an outpatient inflammation center were randomized into an intervention or control group. The intervention group received three standardized educational sessions focusing on maladaptive schemas, coping strategies, psychoeducation, and emotion-focused techniques (e.g. chair-dialogues, imaginary rescripting).<h4>Results</h4>19 patients received the intervention; 13 were in the control group. Post-intervention, significant improvements were observed in dermatological quality of life (DLQI), subjective well-being (WHO-5), and depressive symptoms (PHQ-9, BDI-II). Psychological benefits were largely independent of disease severity (PASI, EASI). Qualitative feedback highlighted usability, learning specific techniques, and a trusting therapeutic relationship.<h4>Conclusions</h4>A brief psychoeducational intervention significantly reduced psychological stress in dermatology outpatients. Further studies are needed to evaluate long-term effects and broader implementation.<p><a href="http://europepmc.org/article/MED/41854066?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">538</guid><pubDate>Mon, 30 Mar 2026 08:02:13 +0000</pubDate></item><item><title>Simulation der Auswirkungen eines edukativen und digitalen Ansatzes unter Verwendung von Patient&#x2010;Journey&#x2010;Modellen, um praktische Herausforderungen bei der Behandlung der chronischen spontanen Urtikaria in Deutschland zu bew&#xE4;ltigen</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/simulation-der-auswirkungen-eines-edukativen-und-digitalen-ansatzes-unter-verwendung-von-patient%E2%80%90journey%E2%80%90modellen-um-praktische-herausforderungen-bei-der-behandlung-der-chronischen-spontanen-urtikaria-in-deutschland-zu-bew%C3%A4ltigen-r508/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/PMC/PMC12968974?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">508</guid><pubDate>Wed, 11 Mar 2026 05:52:25 +0000</pubDate></item><item><title>Lebensqualit&#xE4;t bei Patienten mit vernarbender und nicht vernarbender Alopezie: eine explorative Querschnittsstudie</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/lebensqualit%C3%A4t-bei-patienten-mit-vernarbender-und-nicht-vernarbender-alopezie-eine-explorative-querschnittsstudie-r507/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/PMC/PMC12968979?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">507</guid><pubDate>Wed, 11 Mar 2026 05:52:25 +0000</pubDate></item><item><title>Erfolgreiche Behandlung einer palmoplantaren Pustulose mit Bimekizumab und topischer Photochemotherapie bei gleichzeitig bestehender Hidradenitis suppurativa</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/erfolgreiche-behandlung-einer-palmoplantaren-pustulose-mit-bimekizumab-und-topischer-photochemotherapie-bei-gleichzeitig-bestehender-hidradenitis-suppurativa-r506/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/PMC/PMC12968939?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">506</guid><pubDate>Wed, 11 Mar 2026 05:52:25 +0000</pubDate></item><item><title>S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situations.</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s3-guideline-for-the-treatment-of-psoriasis-vulgaris-adapted-from-euroguiderm-part-2-specific-clinical-and-comorbid-situations-r460/</link><description><![CDATA[The present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities. A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent tuberculosis. The recommendations regarding the use of interferon-gamma release assays and the indication for chest radiography have been extensively revised. In addition, the guidance on the suitability of systemic psoriasis therapies in patients with latent tuberculosis and on the need for preventive antituberculous treatment has been thoroughly updated. In the chapter on inflammatory bowel diseases, risankizumab and guselkumab have been added as recommended treatment options, as both agents have recently been approved for the indications Crohn's disease and ulcerative colitis. Further substantial revisions are included in the chapters on patients with a history of malignancy and viral hepatitis.<p><a href="http://europepmc.org/article/MED/41641952?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">460</guid><pubDate>Sun, 22 Feb 2026 17:23:04 +0000</pubDate></item><item><title>Wohlbefinden bei Patienten mit Vitiligo mit Beteiligung der sichtbaren Hautareale und der Genitalregion in Deutschland&#x2013; eine fragebogengest&#xFC;tzte Pilotstudie</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/wohlbefinden-bei-patienten-mit-vitiligo-mit-beteiligung-der-sichtbaren-hautareale-und-der-genitalregion-in-deutschland-eine-fragebogengest%C3%BCtzte-pilotstudie-r449/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/PMC/PMC12875177?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">449</guid><pubDate>Tue, 10 Feb 2026 08:00:26 +0000</pubDate></item><item><title>Schambezogene St&#xF6;rungen bei Patienten mit atopischer Dermatitis und Psoriasis &#x2013; eine explorative, Querschnitts&#x2010;Interviewstudie zu Pr&#xE4;valenz und Korrelaten k&#xF6;rperdysmorpher St&#xF6;rungen und sozialer Angstst&#xF6;rungen</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/schambezogene-st%C3%B6rungen-bei-patienten-mit-atopischer-dermatitis-und-psoriasis-eine-explorative-querschnitts%E2%80%90interviewstudie-zu-pr%C3%A4valenz-und-korrelaten-k%C3%B6rperdysmorpher-st%C3%B6rungen-und-sozialer-angstst%C3%B6rungen-r448/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/PMC/PMC12875169?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">448</guid><pubDate>Tue, 10 Feb 2026 08:00:26 +0000</pubDate></item><item><title>S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm &#x2013; part 2: Specific clinical and comorbid situations</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s3-guideline-for-the-treatment-of-psoriasis-vulgaris-adapted-from-euroguiderm-part-2-specific-clinical-and-comorbid-situations-r447/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/PMC/PMC12875186?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">447</guid><pubDate>Tue, 10 Feb 2026 08:00:26 +0000</pubDate></item><item><title>S3&#x2010;Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm &#x2013; Teil 2: Hilfestellungen f&#xFC;r besondere klinische Situationen und bei Vorliegen von Komorbidit&#xE4;ten</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s3%E2%80%90leitlinie-zur-therapie-der-psoriasis-vulgaris-adaptiert-von-euroguiderm-teil-2-hilfestellungen-f%C3%BCr-besondere-klinische-situationen-und-bei-vorliegen-von-komorbidit%C3%A4ten-r446/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/PMC/PMC12875179?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">446</guid><pubDate>Tue, 10 Feb 2026 08:00:26 +0000</pubDate></item><item><title>In vivo multiphoton microscopy of psoriasis: A new diagnosis and therapeutic monitoring technique.</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/in-vivo-multiphoton-microscopy-of-psoriasis-a-new-diagnosis-and-therapeutic-monitoring-technique-r435/</link><description><![CDATA[<h4>Background and objectives</h4>Psoriasis is a chronic inflammatory skin disease, and noninvasive diagnostic tools are essential for accurate diagnosis and treatment monitoring. Multiphoton microscopy (MPM) enables real-time, noninvasive skin imaging with submicron resolution. This study evaluated the diagnostic accuracy of MPM in psoriasis and its potential application in therapeutic monitoring.<h4>Patients and methods</h4>This prospective observational study enrolled 34 patients with psoriasis. It comprised three parts: (1) analysis of imaging features of lesional and nonlesional skin using multiphoton microscopy (MPM; Transcend Vivoscope); (2) evaluation of the diagnostic performance of MPM parameters compared with reflectance confocal microscopy (RCM); and (3) prospective monitoring of 24 patients treated with Benvitimod (Tapinarof) cream for 8 weeks (T0/T1/T2).<h4>Results</h4>MPM detected psoriasis characteristics (including hyperkeratosis, parakeratosis, an absent stratum granulosum, enlarged nucleus diameter, and absent bright rimming) with comparable diagnostic efficiency to RCM (AUC = 0.838, p &lt; 0.001 vs. 0.824, p &lt; 0.001). Psoriatic lesions showed significant perinuclear fluorescence accumulation compared to healthy skin (p &lt; 0.001). All imaging features improved significantly after 8 weeks of treatment (p &lt; 0.001). PASI/TLS scores showed correlations with the epidermal thickness (r = 0.403/0.492, p &lt; 0.001), nuclear diameter (r = 0.4/0.375, p &lt; 0.001), and fluorescence intensity (r = -0.419/-0.492, p &lt; 0.001).<h4>Conclusions</h4>MPM is a novel and non-invasive imaging technique for psoriasis evaluation and treatment monitoring.<p><a href="http://europepmc.org/article/MED/41580911?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">435</guid><pubDate>Tue, 03 Feb 2026 08:49:24 +0000</pubDate></item><item><title>Acne tarda: Recommendations for classification, treatment and care as a result of an expert discussion.</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/acne-tarda-recommendations-for-classification-treatment-and-care-as-a-result-of-an-expert-discussion-r424/</link><description><![CDATA[Acne tarda is defined in the literature as adult acne, which according to most authors occurs in women aged 25 and older. However, the definitions and age groups vary depending on the study. Current guidelines rarely address adult acne. In this review, current studies and the literature on acne tarda are analyzed and evaluated by German experts. Recommendations regarding classification, clinical features, differentiation, and treatment of acne tarda were summarized in a consensus based on the discussion. The recommendations also include the treatment of post-inflammatory erythema/hyperpigmentation and acne scars, as well as the accompanying skin care. The goal is to improve the treatment of patients with acne tarda.<p><a href="http://europepmc.org/article/MED/41351204?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">424</guid><pubDate>Sun, 25 Jan 2026 18:42:11 +0000</pubDate></item><item><title>Acne tarda: Empfehlungen zu Einordnung, Therapie und Pflege als Ergebnis einer Expertendiskussion</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/acne-tarda-empfehlungen-zu-einordnung-therapie-und-pflege-als-ergebnis-einer-expertendiskussion-r423/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/PMC/PMC12800892?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">423</guid><pubDate>Sun, 25 Jan 2026 18:42:11 +0000</pubDate></item><item><title>Treatment of Generalized Pustular Psoriasis with Abrocitinib: A Case Report.</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/treatment-of-generalized-pustular-psoriasis-with-abrocitinib-a-case-report-r422/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/MED/41498200?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">422</guid><pubDate>Sun, 25 Jan 2026 18:42:11 +0000</pubDate></item><item><title>Efficacy of upadacitinib in palmoplantar pustulosis case series highlights the complex immune response patterns.</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/efficacy-of-upadacitinib-in-palmoplantar-pustulosis-case-series-highlights-the-complex-immune-response-patterns-r421/</link><description><![CDATA[<h4>Background and objectives</h4>Palmoplantar pustulosis (PPP) is a chronic and refractory inflammatory skin disorder with unclear pathogenesis.<h4>Patients and methods</h4>Ten PPP patients treated with upadacitinib were monitored to assess efficacy and safety. Immunofluorescence and immunohistochemistry were employed to evaluate Th1, Th2, and Th17 cell expressions, along with their associated cytokines in lesions on palms or soles from 16 PPP patients, 10 chronic eczema (CE) patients, 10 psoriasis vulgaris (PV) patients, and 7 healthy controls (HC).<h4>Results</h4>In PPP patients receiving upadacitinib, the shortest time to achieve PPPASI75 and PPPASI90 was 4 weeks and 8 weeks, respectively. The rates of patients achieving PPPASI90 at week 16, week 24, and week 52 was 70 %, 100 %, and100 %, respectively. Th1 cells and IFN-γ levels in PPP were comparable to CE and PV, and higher than HC. Th2 cells, IL-4, and IL-13 levels in PPP were similar to CE, and greater than HC and PV. Th17 cells, IL-17, and IL-36γ levels in PPP were comparable to PV, and more abundant than HC and CE.<h4>Conclusions</h4>Upadacitinib is a safe and effective option for PPP patients, which may be attributed to the complex Th1, Th2, and Th17 inflammatory responses associated with PPP.<p><a href="http://europepmc.org/article/MED/41549598?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">421</guid><pubDate>Sun, 25 Jan 2026 18:42:11 +0000</pubDate></item><item><title>Efficacy of an intervention to reduce stigma towards people with skin diseases among health and body care professionals - a randomized controlled trial.</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/efficacy-of-an-intervention-to-reduce-stigma-towards-people-with-skin-diseases-among-health-and-body-care-professionals-a-randomized-controlled-trial-r420/</link><description><![CDATA[<h4>Background and objectives</h4>People with skin disease often experience stigmatization in health and body care settings, significantly impacting their quality of life. This parallel-group randomized controlled trial evaluated a face-to-face group seminar aimed at reducing stigma towards people with skin disease among health and body care professionals (HBCPs).<h4>Patients and methods</h4>Cosmetologists, hairdressers, nurses, and physical therapists were randomized into an intervention (IG; n = 64) or control group (CG; n = 65). The IG received a seminar consisting of self-awareness exercises, education and a patient encounter; the CG followed a seminar on "health at work". Stereotype agreement, disease-related misconceptions, desire for social distance, and behavioral intentions were assessed at baseline (t0), post-intervention (t1), and 3 months follow-up (t2).<h4>Results</h4>The intervention group showed significant reductions over time in disease-related misconceptions (t0-t1: 0.398, p &lt; 0.001; t0-t2: 0.225, p &lt; 0.001; ηp<sup>2</sup> = 0.12) and in stereotype endorsement (t0-t1: 0.392, p &lt; 0.001; t0-t2: 0.299, p = 0.002; ηp<sup>2</sup> = 0.12). In both groups, the desire for social distance decreased immediately after the seminar (t0-t1<sub>Intervention</sub>: 0.186, p &lt; 0.001; t0-t1<sub>Control</sub>: 0.135, p = 0.012) but returned to baseline at follow-up (t0-t2<sub>Intervention</sub>: 0.097, p = 0.35; t0-t2<sub>Control</sub>: 0.016, p = 1.00).<h4>Conclusions</h4>The seminar improved skin disease-related stigmatizing beliefs and attitudes of HBCPs. Its integration into vocational training curricula or delivery in workshops to increase knowledge about skin diseases and to reduce prejudices in various professional groups is promising.<p><a href="http://europepmc.org/article/MED/41546158?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">420</guid><pubDate>Sun, 25 Jan 2026 18:42:11 +0000</pubDate></item><item><title>S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 1: Treatment recommendations and monitoring.</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s3-guideline-for-the-treatment-of-psoriasis-vulgaris-adapted-from-euroguiderm-part-1-treatment-recommendations-and-monitoring-r419/</link><description><![CDATA[This first part of the updated German S3 guideline on the treatment of psoriasis vulgaris covers the sections on treatment recommendations, treatment goals, and monitoring of therapies. The recommendations are based on the current Cochrane network meta-analysis, the results of which are also summarized. When selecting systemic therapies for psoriasis vulgaris, the guideline emphasizes consideration of efficacy, safety, comorbidities, and individual patient factors. The decision framework is presented in the treatment options overview, and in this updated version, the possibility of first-line therapy with biologics or novel targeted small molecules is more prominently highlighted. Standardized instruments for assessing disease severity, as well as patient-centered treatment goals, are underscored. A Psoriasis Area and Severity Index (PASI) 75 response is defined as the minimum therapeutic target, while PASI 90 or an absolute PASI &lt;2 are considered desirable goals. Since the last version, two newly approved agents, bimekizumab and deucravacitinib, have been incorporated, accompanied by specific usage recommendations. Among the established therapies, guidance on methotrexate has been extensively revised, particularly regarding administration, dosing, and monitoring. This guideline aims to provide clinicians with an evidence-based framework for therapy selection and monitoring, while strengthening shared decision-making with patients.<p><a href="http://europepmc.org/article/MED/41531416?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">419</guid><pubDate>Sun, 25 Jan 2026 18:42:11 +0000</pubDate></item><item><title>S3&#x2010;Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm &#x2013; Teil 1: Therapieempfehlungen und Monitoring</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s3%E2%80%90leitlinie-zur-therapie-der-psoriasis-vulgaris-adaptiert-von-euroguiderm-teil-1-therapieempfehlungen-und-monitoring-r418/</link><description><![CDATA[<small>No abstract supplied.</small><p><a href="http://europepmc.org/article/PMC/PMC12800869?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">418</guid><pubDate>Sun, 25 Jan 2026 18:42:11 +0000</pubDate></item><item><title>In vivo multiphoton microscopy of psoriasis: A new diagnosis and therapeutic monitoring technique.</title><link>https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/in-vivo-multiphoton-microscopy-of-psoriasis-a-new-diagnosis-and-therapeutic-monitoring-technique-r417/</link><description><![CDATA[Psoriasis is a chronic inflammatory skin disease, and noninvasive diagnostic tools are essential for accurate diagnosis and treatment monitoring. Multiphoton microscopy (MPM) enables real-time, noninvasive skin imaging with submicron resolution. This study evaluated the diagnostic accuracy of MPM in psoriasis and its potential application in therapeutic monitoring. This prospective observational study enrolled 34 patients with psoriasis. It comprised three parts: (1) analysis of imaging features of lesional and nonlesional skin using multiphoton microscopy (MPM; Transcend Vivoscope); (2) evaluation of the diagnostic performance of MPM parameters compared with reflectance confocal microscopy (RCM); and (3) prospective monitoring of 24 patients treated with Benvitimod (Tapinarof) cream for 8 weeks (T0/T1/T2). MPM detected psoriasis characteristics (including hyperkeratosis, parakeratosis, an absent stratum granulosum, enlarged nucleus diameter, and absent bright rimming) with comparable diagnostic efficiency to RCM (AUC = 0.838, p &lt; 0.001 vs. 0.824, p &lt; 0.001). Psoriatic lesions showed significant perinuclear fluorescence accumulation compared to healthy skin (p &lt; 0.001). All imaging features improved significantly after 8 weeks of treatment (p &lt; 0.001). PASI/TLS scores showed correlations with the epidermal thickness (r = 0.403/0.492, p &lt; 0.001), nuclear diameter (r = 0.4/0.375, p &lt; 0.001), and fluorescence intensity (r = -0.419/-0.492, p &lt; 0.001). MPM is a novel and non-invasive imaging technique for psoriasis evaluation and treatment monitoring.<p><a href="http://europepmc.org/article/MED/41580911?source=rss" rel="external nofollow">Weiterlesen</a></p>]]></description><guid isPermaLink="false">417</guid><pubDate>Sun, 25 Jan 2026 18:42:11 +0000</pubDate></item></channel></rss>
